Form 4: Beta Bionics CFO Stephen Feider Reports Stock Option Grant

Stephen Feider, CFO of Beta Bionics, reports the acquisition of stock options exercisable for 186,203 shares of common stock.

Summary

• Stephen Feider, the Chief Financial Officer of Beta Bionics, Inc., filed a Form 4 on January 31, 2025.
• The form reports a transaction on January 29, 2025, where Feider acquired options to purchase 186,203 shares of Beta Bionics' Class B Common Stock (now Common Stock after IPO conversion).
• The exercise price of the options is $17.
• The options vest monthly over a 48-month period starting January 29, 2025, and expire on January 28, 2035.
• Feider directly owns 186,203 derivative securities following the reported transaction.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing related to stock option grants, which is neither particularly positive nor negative. It's a routine part of corporate governance.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates that the CFO has been granted stock options, which is a common practice to align management's interests with those of shareholders.

Stakeholder Impact

• The granting of stock options to the CFO aligns his interests with those of shareholders, potentially incentivizing him to improve company performance.

Key Dates